Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–ImmunogenX is pleased to announce that patient enrollment has begun for a Phase 2b clinical trial (NCT04243551, named ?Solutions for Celiac??). This trial is funded by the National Institutes of Health?s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) as a grant to ImmunogenX. The multi-center trial includes Columbia University in New York, NY; Mayo Clinic in Rochester, MN; and private practice sites located in the US. This trial will